Blood tests to predict outcomes in sudden IPF flare-ups
Part of Lungs & breathing clinical trials.
This study looks at whether simple blood tests done when you are admitted to the hospital for a sudden worsening of pulmonary fibrosis (called an acute exacerbation) can help predict how you will do. This might help doctors plan better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF).
- You are being admitted to the hospital for a sudden worsening of your breathing that has lasted less than one month.
- Your worsening is not caused by another condition like pneumonia, a blood clot in the lung, heart failure, or a collapsed lung.
- Your IPF is not due to another cause like connective tissue disease, exposure to dusts, sarcoidosis, or certain medications.
- You have not had cancer treatment (chemotherapy, radiation, or other immune-suppressing drugs) in the last 30 days, and you do not have an active cancer or a blood disorder like leukemia or lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
This study looks at people with idiopathic pulmonary fibrosis (IPF) who are currently having a sudden worsening of breathing symptoms. It may help doctors better understand what happens during these flare-ups and how to manage them.
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
This study looks at people with a condition called idiopathic pulmonary fibrosis (IPF), which causes lung scarring. Researchers want to develop a tool to predict how the disease will progress, so they will collect health data over time to see what factors affect outcomes.
This study looks at how well people with pulmonary fibrosis can breathe in and aims to see if their breathing flow rate is linked to their condition. It may help doctors understand more about the disease and plan better care.
This trial tests a treatment that reduces certain antibodies in your blood, which may help slow the progression of IPF. The treatment involves a procedure to filter your blood and then giving you antibodies to help your immune system.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.